Webster Equity is bringing addiction treatment provider BayMark Health to market, two sources familiar tell Axios Pro. It’s Webster’s second time trying to sell BayMark, which the sponsor put in a continuation vehicle in 2021. The firms explored a sale via Goldman Sachs in 2019, but the process was shelved. At the time, BayMark was marketing on $90 million of adjusted EBITDA and $75 million of actual EBITDA. Webster moved BayMark and Pharmalogic into the CV in 2021. That was led by Coller Capital and Morgan Stanley with a large syndicate, and valued at just over $1 billion.
Read the full article: Webster Equity Bringing BayMark Health to Market //
Source: https://www.axios.com/pro/health-tech-deals/2025/06/26/webster-equity-selling-baymark-health